REGENXBIO Inc. (RGNX)
NASDAQ: RGNX · Real-Time Price · USD
10.72
-0.56 (-4.96%)
At close: Aug 7, 2026, 4:00 PM EDT
10.74
+0.02 (0.19%)
Pre-market: Aug 10, 2026, 8:11 AM EDT
REGENXBIO Revenue
REGENXBIO had revenue of $108.02M in the quarter ending June 30, 2026, with 405.73% growth. This brings the company's revenue in the last twelve months to $174.48M, up 12.00% year-over-year. In the year 2025, REGENXBIO had annual revenue of $170.44M with 104.54% growth.
Revenue (ttm)
$174.48M
Revenue Growth
+12.00%
P/S Ratio
4.06
Revenue / Employee
$470,302
Employees
371
Market Cap
707.66M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 170.44M | 87.11M | 104.54% |
| Dec 31, 2024 | 83.33M | -6.91M | -7.66% |
| Dec 31, 2023 | 90.24M | -22.48M | -19.94% |
| Dec 31, 2022 | 112.72M | -357.62M | -76.03% |
| Dec 31, 2021 | 470.35M | 315.78M | 204.30% |
| Dec 31, 2020 | 154.57M | 119.33M | 338.70% |
| Dec 31, 2019 | 35.23M | -183.27M | -83.88% |
| Dec 31, 2018 | 218.51M | 208.11M | 2,002.42% |
| Dec 31, 2017 | 10.39M | 5.80M | 126.48% |
| Dec 31, 2016 | 4.59M | -3.00M | -39.52% |
| Dec 31, 2015 | 7.59M | 1.47M | 23.99% |
| Dec 31, 2014 | 6.12M | 33.00K | 0.54% |
| Dec 31, 2013 | 6.09M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Phathom Pharmaceuticals | 239.66M |
| Zevra Therapeutics | 136.07M |
| Gyre Therapeutics | 109.82M |
| Crescent Biopharma | 11.88M |
| Neurogene | 925.00K |
| Allogene Therapeutics | 22.00K |
RGNX News
- 2 hours ago - Regenxbio price target lowered to $23 from $26 at H.C. Wainwright - TheFly
- 2 days ago - Regenxbio price target raised to $18 from $16 at Morgan Stanley - TheFly
- 3 days ago - Regenxbio downgraded to Equal Weight from Overweight at Barclays - TheFly
- 4 days ago - REGENXBIO Earnings Call Transcript: Q2 2026 - Transcripts
- 4 days ago - REGENXBIO Earnings release: Q2 2026 - Filings
- 4 days ago - REGENXBIO Quarterly report: Q2 2026 - Filings
- 4 days ago - Regenxbio reports Q2 EPS 43c vs. ($1.38) last year - TheFly
- 4 days ago - REGENXBIO Reports Second Quarter 2026 Financial Results and Operational Highlights - PRNewsWire